TumorDiagnostik & Therapie, Table of Contents TumorDiagnostik & Therapie 2017; 38(01): 40-42DOI: 10.1055/s-0042-124067 Schwerpunkt Neuroendokrine Neoplasien © Georg Thieme Verlag KG Stuttgart · New York Medikamentöse Therapie neuroendokriner Neoplasien Sebastian Noe Recommend Article Abstract Buy Article Full Text References Literatur 1 Falconi M. Eriksson B. Kaltsas G. et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinol 2016; 103: 153-171 2 Pavel M. O'Toole D. Costa F. et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016; 103: 172-185 3 Pavel M. Hörsch D. Caplin M. et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab 2015; 100: 1511-1519 4 Kulke MH. O'Dorisio T. Phan A. et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer 2014; 21: 705-714 5 Rinke A. Mueller HH. Schade-Brittinger C. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663 6 Caplin ME. Pavel M. Cwikla JB. et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371: 224-233 7 Rinke A. Wittenberg M. Schade-Brittinger C. et al. Placebo Controlled, Double Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results on Long Term Survival. Neuroendocrinol 2017; 104: 26-32 8 Zatelli MC. Fanciulli G. Malandrino P. et al. Predictive factors of response to mTOR inhibitors in neuroendocrine tumours. Endocr Relat Cancer 2016; 23: 173-183 9 Pusceddu S. DeBraud F. Lo Russo G. et al. How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. Oncotarget 2016;
